INS and type 2 diabetes mellitus: 2-3-week early CSII in patients with newly diagnosed T2DM in Chinese population achieved prolonged glycaemic remission, as well as recovery and maintenance of β-cell function compared with treatment with oral hypoglycaemic agents; this early insulin replacement could achieve optimum glycaemic control for 1 year [14].